Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
61,778,278
-
Total 13F shares
-
39,115,323
-
Share change
-
+2,113,168
-
Total reported value
-
$307,072,298
-
Put/Call ratio
-
375%
-
Price per share
-
$7.85
-
Number of holders
-
77
-
Value change
-
+$16,197,029
-
Number of buys
-
45
-
Number of sells
-
24
Institutional Holders of Aura Biosciences, Inc. - Common Stock (AURA) as of Q1 2024
As of 31 Mar 2024,
Aura Biosciences, Inc. - Common Stock (AURA) was held by
77 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
39,115,323 shares.
The largest 10 holders included
Matrix Capital Management Company, LP, EVENTIDE ASSET MANAGEMENT, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., CITADEL ADVISORS LLC, Medicxi Ventures Management (Jersey) Ltd, BlackRock Inc., VANGUARD GROUP INC, FRANKLIN RESOURCES INC, Nantahala Capital Management, LLC, and GOLDMAN SACHS GROUP INC.
This page lists
77
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.